Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant.

Bento, Dulce; Jesus, Sandra; Lebre, Filipa; Gonçalves, Teresa; Borges, Olga

Bento, Dulce; Jesus, Sandra; Lebre, Filipa; Gonçalves, Teresa; Borges, Olga.

Afiliación

Bento D; CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-0504 Coimbra, Portugal. sjesus.mg@gmail.com.
Jesus S; Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal. sjesus.mg@gmail.com.
Lebre F; CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-0504 Coimbra, Portugal. filipalebre@sapo.pt.
Gonçalves T; Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal. filipalebre@sapo.pt.
Borges O; CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-0504 Coimbra, Portugal. tgoncalves@fmed.uc.pt.

Pharmaceutics ; 11(2)2019 Feb 09.

Article en En | MEDLINE | ID: mdl-30744102

Palabras clave

chitosan; compound 48/80; mast cell activator; nanoparticles; nasal vaccination; vaccine adjuvant

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pharmaceutics Año: 2019 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google